1 / 1
Quviviq(Daridorexant)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
Idorsia
Formulation:
TABLET
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of
a
pharmacist. For read by medical and pharmaceutical professionals only.
Quviviq(Daridorexant) Instructions:Uses,Dosage, Side Effects
Daridorexant, developed by Idorsia, a Swiss company, is an innovative dual orexin receptor antagonist that brings a new treatment option for insomnia patients.
Daridorexant was approved for marketing by the U.S. FDA in January 2022, and has since been successively approved in the UK, the European Union, Switzerland, Canada and other places, demonstrating its remarkable efficacy and safety.
As the fourth-generation anti-insomnia drug, Daridorexant effectively improves difficulty falling asleep and sleep maintenance problems by precisely regulating the sleep-wake pathway, with fewer side effects and no addictive potential.
